Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Shareholder Meeting (December 2023)
19 slides from Alterity Therapeutics's shareholder meeting presentation, Dec 29, 2023
Slide 1: Alterity Therapeutics
Alterity Therapeutics (NASDAQ:ATHE, ASX:ATH) David Stamler, MD EGM – 29 December 2023 CEO
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain some statements that may be considered “Forward-Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward-looking statement relating to financial projections or other statements relating to the Company’s plans, objec
Slide 3: Overview of Today's Presentation
Overview of Today’s Presentation • New Primate data with ATH434 • Update on our clinical programs • Looking forward to 2024 3
Slide 4: Parkinsonian Disorders: A Significant Unmet Need
Parkinsonian Disorders: A Significant Unmet Need • Parkinsonism is a syndrome of motor symptoms that PARKINSONIAN DISORDERS includes slowed movement, stiffness and tremor • Parkinson’s disease most common cause • Major source of disability MSA • Parkinsonian disorders include Multiple System Atrophy
Slide 5: Increased Brain Iron in Parkinson's Disease and Related Disorders
Increased Brain Iron in Parkinson’s Disease and Related Disorders Parkinson’s disease Multiple System Atrophy n=7 * Patients Substantia nigra (T) n=8 n=9 Cerebral cortex Healthy n = 11 n=8 * Substantia nigra (pc) n=3 n=8 * Caudate nucleus n = 13 n = 10 Cerebellum n = 24 n=8 * 0 10000 20000 30000 Put
Slide 6: Excess Iron and Alpha-Synuclein are Strong Contributors to Disease Pathology
Excess Iron and Alpha-Synuclein are Strong Contributors to Disease Pathology Oxidative Stress α-Synuclein: protein critical for normal function of neurons • Adverse impact of excess iron • Promotes α-synuclein aggregation/clumping Neuroinflammation Iron Imbalance • Root cause of oxidative stress whi
Slide 7: Approach: Address Underlying Pathology of Disease
Approach: Address Underlying Pathology of Disease Reduce α‐synuclein Redistribute excess iron aggregation Rescue neuronal in the Central Nervous System and function Oxidative stress Potential Disease Modifying Therapy 7
Slide 8: ATH434: Disease Modifying Drug Candidate
ATH434: Disease Modifying Drug Candidate • ATH434 redistributes excess iron and reduces α‐synuclein clumping in brain • Oral agent (tablet) for ease of use • Readily absorbed, shown to reach site of action in man • Potential to treat various Parkinsonian disorders • Orphan Drug Designation in the US
Slide 9: Primate Study Validates ATH434 Clinical Approach
Primate Study Validates ATH434 Clinical Approach Promising New Data • Well established model of Parkinson’s, primate closer to humans • ATH434 treatment improved motor skills and general behavior in monkeys with experimentally induced Parkinson’s disease • Favorable impact on Parkinson’s symptoms in
Slide 10: Monkey Parkinson's Disease Study
Monkey Parkinson’s Disease Study Disease Onset Baseline Daily oral doses Train, habituate Placebo vs ATH434 3 mg/kg vs ATH434 10 mg/kg Week 0 4 8 12 12 - 14 Motor Assessment Motor Assessment Motor Assessment Measure Brain Iron Source: Bradbury, et al, “Effects of ATH434, a Clinical-Phase Small Molec
Slide 11: ATH434 Improved Motor and Behavior Scores
ATH434 Improved Motor and Behavior Scores Improvement Associated with Reduced Iron General Motor General Behavior 8 24 6 18 Score** Score * 4 12 2 Lowest Lowest 6 Iron Iron Levels Levels 0 better better 0 Baseline Week 12 Baseline Week 12 * Fine motor skills, eating, eyeblink Placebo (veh) ** Appeti
Slide 12: Accumulated Data Supports ATH434 Efficacy
Accumulated Data Supports ATH434 Efficacy Neurons/ Clinical Target Disease Model Brain Iron α-Synuclein Author Connectivity Observations Improved motor Parkinson’s disease Mouse MPTP Finkelstein performance Improved motor Parkinson’s disease Mouse A53T Finkelstein performance Improved mo
Slide 13: Clinical Development Progress in Multiple System Atrophy
Clinical Development Progress in Multiple System Atrophy 13
Slide 14: Promising Portfolio in Neurodegenerative Diseases
Promising Portfolio in Neurodegenerative Diseases ASSET PHASE PARTNER PRE- NATURAL PARTNER / PROGRAM INDICATION DISCOVERY PHASE 1 PHASE 2 CLINICAL HISTORY COLLABORATOR Multiple System Atrophy ATH434-201 Enrollment Complete Early Stage Multiple System Atrophy ATH434-202 Advanced Multiple System Atrop
Slide 15: Clinical Development in MSA
Clinical Development in MSA Study ATH434-201 – Phase 2 ATH434-202 – Phase 2 bioMUSE – Natural History Randomized, double-blind, Design Single arm, open-label Observational placebo controlled Efficacy and safety of ATH434 Efficacy and safety of ATH434 Design and de-risk Phase 2 Objectives Assess targ
Slide 16: Significant Commercial Opportunity in Treating Multiple System Atrophy
Significant Commercial Opportunity in Treating Multiple System Atrophy Substantial Unmet Need Strong Intent to Prescribe Severely debilitating illnesses Motivated by efficacy of treating with no current treatments are the underlying disease and not ripe for new entrants targeting just the symptoms,
Slide 17: Key Milestones
Key Milestones Enrollment Complete ATH434-201 Phase 2 Trial Data with ATH434 in Monkey Model Study Complete of Parkinson’s ATH434-201 Disease Phase 2 Trial bioMUSE Data Preliminary Data from ATH434-202 Open Label Biomarker Trial Oct Nov Dec Jan Feb Mar Apr May Jun July Aug Sep Oct Nov Dec Jan 23 23
Slide 18: Poised for Progress in 2024
Poised for Progress in 2024 • New primate data validates our clinical strategy • Achieved all clinical and corporate milestones in 2023 • ATH434: Novel drug candidate for various parkinsonian disorders • First indication: Multiple System Atrophy (MSA) • ATH434-201 (early-stage MSA): Fully enrolled •
Slide 19: Therapeutics
THERAPEUTICS
Alterity Therapeutics — Shareholder Meeting (December 2023) on 6ix